Roche’s Genentech More than Doubles North Carolina Facility Investment to $2B

San Francisco-based biotech company doubles down

(The Center Square) – Genentech, a San Francisco-based biotech company, has decided to more than double its investment in a new drug manufacturing facility in North Carolina.

Roche’s Genentech more than doubles North Carolina facility investment to $2B

The 700,000-square-foot project broke ground in August and is set to produce weight-loss treatments by 2029 in Holly Springs, a growing biopharmaceutical hub.

Roche boosts NC factory investment to $2B; Rentschler CEO steps down

Roche’s Genentech is topping up its investment into its Holly Springs, NC, factory to reach nearly $2 billion. The extra investment will also add an additional 100 jobs at the site ...

Expanded Investment Will Allow Genentech’s East Coast Manufacturing Facility to Boost Production Output

Genentech increased its investment in a new Holly Springs, NC manufacturing facility. The company’s financial decision will more than double the initial total commitment for the company’s first East Coast manufacturing facility to approximately $2 billion. This investment is on top of the initial commitment in May 2025, and groundbreaking in August 2025, reflecting Genentech’s continued confidence in the region’s community, workforce, and long-t…